Work

Planned Analyses of the REDUCE MRSA Trial

Year: 2014

Type: letter

Abstract: In their recent commentary, Kavanagh et al. (1) provided a per-spective on recent clinical trials and guidance that raised ques-tions about the universal utility of active screening and contact precautions as the ideal strategy to combat methicillin-resistant Staphylococcus aureus (MRSA). As investigators of the REDUCE MRSA Trial, we would like to provide the following clarifications related to the description of our secondary outcomes. First, the REDUCEMRSA trial has several a priori secondary outcomes, only some of which were intended for inclusion in the primary report. In addition to our primary outcome of MRSA clinical cultures attributed to the intensive care unit (ICU), we reported the secondary outcomes of MRSA bloodstream infections and all-cause bloodstream infections in a recently published report (2). However, addi-tional secondary outcomes are under way and include an as-sessment of urinary tract infections and blood culture contam-

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.02792-13

Authors: Susan S. Huang, Richard Platt

Institutions: University of California, Irvine, Harvard University, Harvard Pilgrim Health Care

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2029478931

Cites: 4

Cited by: 4

Related to: 10